FDA Approves Osimertinib With Chemotherapy for EGFRm NSCLC

Osimertinib was previously approved as a monotherapy, the first-in-line global standard of care, for non–small cell lung cancer indications.

Related Keywords

,Davida Litman ,Dave Fredrickson ,Astrazeneca ,Dana Farber Cancer Institute ,Osimertinib With ,Line Treatment ,Completion Date ,Oncology Business Unit ,Thenew England Journal ,Yang Jc H ,Mutated Advanced ,